Kazia Therapeutics (Kazia Therapeutics) Price-to-Operating-Cash-Flow : (As of Apr. 24, 2024)

View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-04-24), Kazia Therapeutics's share price is $0.389. Kazia Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.60. Hence, Kazia Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Kazia Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

KZIA's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.92
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Kazia Therapeutics's Cash Flow from Operations per share for the six months ended in Jun. 2023 was $-0.19. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.60.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 12.80% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 9.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 17.20% per year.

During the past 13 years, Kazia Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 62.20% per year. The lowest was -65.10% per year. And the median was 21.10% per year.

Kazia Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Kazia Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Price-to-Operating-Cash-Flow Chart

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Kazia Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Kazia Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Kazia Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kazia Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's Price-to-Operating-Cash-Flow falls into.

Kazia Therapeutics Price-to-Operating-Cash-Flow Calculation

Kazia Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.389	/	-0.599
	=

Kazia Therapeutics's Share Price of today is $0.389.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kazia Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.60.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Kazia Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204